



**Response document for MHRA public consultation on the
proposal to make Nasonex Allergy Control available in Pharmacies
Ref: ARM92**

Your details

Name: [redacted]

Position (if applicable): Registrar

Organisation (if applicable): Royal College of Physicians (RCP)

Email: [redacted]

1. Do you consider that Nasonex Allergy Control should be available as a Pharmacy medicine?

Yes No Not sure

Please provide any comments or evidence to support your response:

The pharmacology and adverse effects are well-known. There are no major additional risks compared to other similar preparations of nasal corticosteroids that are currently available on the market without prescription.

2. Do you have any specific comments on the leaflet or the label provided in the public reclassification report for Nasonex Allergy Control?

3. Do you have any other comments on the reclassification?

4. The MHRA may publish consultation responses. Do you want your response to remain confidential?

Yes Partially* No

*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gsi.gov.uk) to arrive by **12 December 2016**. Contributions received after that date cannot be included in the exercise.